Scarring alopecia is a group of conditions that cause permanent hair loss by destroying hair follicles and replacing them with scar tissue. Unlike common hair loss (like male or female pattern baldness), where follicles shrink but remain alive, scarring alopecia eliminates the follicle entirely. Once that happens, hair cannot regrow in the affected area. The conditions are uncommon but not rare, and early treatment is critical to preserving as much hair as possible.
How It Differs From Other Hair Loss
In most types of hair loss, the follicle itself stays intact. It may produce thinner, weaker hair or stop producing hair temporarily, but the biological machinery is still there. Scarring alopecia is fundamentally different. The follicle’s stem cells, which sit in a region called the bulge, are destroyed by inflammation. The body replaces the follicle with connective (scar) tissue, and the tiny openings in the skin where hair once emerged close permanently. That closure of the follicular openings is one of the key signs a dermatologist looks for when distinguishing scarring from non-scarring hair loss.
The destruction typically happens in stages. First, inflammation targets the upper portion of the follicle. Over time, the follicle breaks down, sometimes trapping fragments of the hair shaft inside, which triggers further inflammation. Eventually, scar tissue fills in where the follicle used to be. Nearby follicles can fuse together at the surface, creating clusters where two or three hairs emerge from what looks like a single opening.
Early Warning Signs
Scarring alopecia usually shows up as one or more bald patches where the skin looks smooth and shiny, lacking the tiny pores you’d normally see on a healthy scalp. But the visual signs alone don’t always tell the full story. Many people notice symptoms before the hair loss becomes obvious: itching, burning, tingling, or tenderness in areas of the scalp that previously felt normal. These sensations reflect active inflammation around the follicles.
Other signs can include redness, flaky or scaling skin, small inflamed bumps, pustules, crusting, or blisters around the affected area. Some people notice skin discoloration. The pattern and combination of these symptoms vary depending on which specific type of scarring alopecia is involved.
Primary vs. Secondary Types
Scarring alopecias fall into two broad categories. In primary scarring alopecia, the hair follicle itself is the main target of an inflammatory or immune process. In secondary scarring alopecia, something external destroys the follicle: burns, radiation therapy, severe bacterial or fungal infections, physical trauma, or conditions like localized scleroderma.
Primary scarring alopecias are further classified by the type of immune cell driving the inflammation: lymphocytic (the most common group), neutrophilic, or mixed. This distinction matters because it guides treatment. The most frequently diagnosed conditions include lichen planopilaris, frontal fibrosing alopecia, central centrifugal cicatricial alopecia, discoid lupus, and folliculitis decalvans.
Lichen Planopilaris and Frontal Fibrosing Alopecia
Lichen planopilaris (LPP) is a lymphocytic scarring alopecia that typically produces irregular patches of hair loss, most often on the top of the scalp. The patches can be single or scattered across multiple areas without a predictable pattern. Under a microscope, the hallmark is a dense cuff of immune cells surrounding the upper follicle.
Frontal fibrosing alopecia (FFA) is considered a variant of LPP, sharing the same microscopic features, but it behaves differently on the surface. FFA causes a slow, symmetrical recession of the hairline along the front and sides of the scalp. Eyebrow loss on both sides is extremely common and is one of the major diagnostic criteria. Some people also lose body hair, develop small skin-colored bumps on the face, or notice prominent veins on the forehead as the hairline moves back. FFA has become notably more common in recent decades, particularly in postmenopausal women, though it can affect men and younger women as well.
A rarer subtype called Graham Little-Piccardi-Lassueur syndrome combines scarring hair loss on the scalp with non-scarring hair loss in the armpits and pubic area, along with small rough bumps on the trunk and limbs.
Central Centrifugal Cicatricial Alopecia
CCCA is the single most common form of scarring alopecia overall. It predominantly affects Black women between the ages of 30 and 55, with a prevalence estimated at 2.7% to 5.6% in that population. The hair loss begins at the crown and spreads outward in a circular pattern, which is where the name “centrifugal” comes from.
The causes are likely a combination of genetic susceptibility and environmental triggers. Mutations in a gene involved in hair shaft development (PADI3) have been linked to CCCA. On the environmental side, traction hairstyles and chemical hair relaxers have been associated with increased risk in some studies, though not all research agrees on the strength of that connection. The working theory is that an external insult to the scalp sets off an immune response that, in genetically predisposed individuals, becomes self-sustaining.
CCCA also has notable links to other health conditions. Type 2 diabetes has been positively associated with CCCA across multiple studies. Uterine fibroids, high cholesterol, and vitamin D deficiency have also shown associations, though the research is thinner. The severity of CCCA tends to correlate with age and total years of hair loss, which underscores why early intervention matters.
Discoid Lupus on the Scalp
Discoid lupus erythematosus (DLE) is a form of chronic skin lupus that frequently involves the scalp. It starts as red, inflamed patches that can progress to white, hairless areas with visible scaling and plugged follicles. Over time, if left untreated, these patches develop irreversible scarring. Younger age at onset and chronic, long-standing disease both increase the risk of permanent hair loss. DLE can occur on its own or as part of systemic lupus, so people diagnosed with scalp DLE are typically monitored for broader autoimmune involvement.
How Scarring Alopecia Is Diagnosed
A dermatologist can often suspect scarring alopecia based on the pattern of hair loss and the absence of visible follicular openings, but clinical signs alone frequently overlap between different types. A scalp biopsy is considered the definitive diagnostic step. A small sample of skin is taken using a circular punch tool (about 4 millimeters wide), ideally from an area at the edge of the hair loss patch where inflammation is active but some follicles still remain. This gives pathologists the best chance of identifying the type of immune cells involved and the stage of follicle destruction.
Dermoscopy, which uses a magnifying instrument to examine the scalp surface closely, is a useful first step. It can reveal perifollicular redness, scaling around individual follicles, and the loss of follicular openings, all of which point toward a scarring process. Dermatologists also use activity scoring systems to track disease progression. For LPP and FFA, the Lichen Planopilaris Activity Index combines symptoms (itch, pain, burning), visual signs (redness, scaling), and whether the disease appears to be worsening to generate a score from 0 to 10.
Treatment Goals and Options
Because destroyed follicles cannot regenerate, the primary goal of treatment is stopping the inflammation before more hair is lost. Hair that’s already gone from fully scarred areas will not come back with medical therapy alone. This is why dermatologists emphasize early diagnosis and aggressive management of active disease.
Standard treatments have traditionally relied on anti-inflammatory and immune-suppressing approaches: topical and injected corticosteroids, antimalarial medications (particularly for DLE and LPP), and various oral immune-modulating drugs depending on the specific type. The choice depends on how active and widespread the disease is.
A newer class of treatments, JAK inhibitors, has shown promising early results. These drugs work by blocking specific immune signaling pathways involved in the inflammatory cascade that damages follicles. In a study of 41 patients with FFA and LPP, a topical JAK inhibitor cream reduced disease activity scores by 48% at six months, and over 92% of FFA patients showed improvement or stabilization of their hairline. Oral forms have also shown benefit: in a phase 2 trial of 50 patients with LPP, FFA, and CCCA, one oral JAK inhibitor reduced disease activity by 51% at 24 weeks and 79% at 48 weeks in LPP patients. CCCA patients in the same trial experienced a 43.5% reduction in hair loss severity at 48 weeks.
These results are encouraging, but the research also highlights a key limitation. In one case series of patients with folliculitis decalvans (a neutrophilic scarring alopecia), all patients relapsed within a year of stopping the medication. This suggests that some forms of scarring alopecia may require ongoing treatment to maintain control.
For areas where scarring is complete and stable (no longer actively inflamed), hair transplantation is sometimes an option, though success rates vary and the procedure is only considered once the disease has been quiet for an extended period.
Living With Scarring Alopecia
The psychological impact of scarring alopecia is significant. Permanent, visible hair loss affects self-image, and the unpredictability of flares can be stressful. Many people benefit from connecting with patient communities like the Cicatricial Alopecia Research Foundation, which provides educational resources and peer support.
Practically, protecting the scalp from sun exposure in areas of hair loss is important, since the skin in scarred patches is more vulnerable to UV damage. Avoiding hairstyles that place tension on fragile areas, minimizing chemical treatments, and using gentle hair care practices can help reduce additional stress on remaining follicles, particularly in conditions like CCCA where traction and chemicals may contribute to disease progression.